Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
There is strong scientific rationale for exploring the role of sorafenib with capecitabine
and cisplatin (XP) in AGC. XP is a new standard of care in AGC and sorafenib is a novel
signal transduction inhibitor that prevents tumor cell proliferation and angiogenesis through
blockade of the Raf/MEK/ERK pathway at the level of Raf kinase and the receptor tyrosine
kinases VEGF-R2 and PDGFR-beta.